1. Carratt SA, Braun TP, Coblentz C, ​Schonrock Z, Callahan R, Smith B, Maloney L, Foley AC and Maxson JE. Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia. Leukemia (2021). https://doi.org/10.1038/s41375-021-01278-2.
2. Braun TP, Estabrook J, Coleman D, Schonrock Z, Smith B, Enright T, Coblentz C, Callahan R, Druker BJ, Lusardi T and Maxson JE. ASXL1 Directs Neutrophilic Differentiation via Modulation of MYC and RNA Polymerase II. Biorxiv doi: https://doi.org/10.1101/2020.09.14.295295.
3. Carratt SA, Brewer D, Maxson JE, Druker BJ and Braun TP. Outgrowth of a CSF3R-mutant clone drives secondary myeloproliferative neoplasm in a chronic myeloid leukemia patient. Biomark Res. 2021 Jan 30;9(1):8.
4. Braun TP, Coblentz C, Smith BM, Coleman DJ, Schonrock Z, Carratt SA, Callahan RL, Maniaci B, Druker BJ, Maxson JE. Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia. PNAS. 2020 Jun 16;117(24):13670-13679.
5. Stoner RC, Press RD, Maxson JE, Tyner JW, Dao KT. Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy. Leukemia. 2020 Jun;34(6):1684-1688.
6. Tarlock K, Alonzo T, Wang YC, Gerbing RB, Ries RE, Hylkema T, Smit J, Maxson JE, Meshinchi S. Prognostic Impact of CSF3R Mutations in Favorable Risk Childhood Acute Myeloid Leukemia. Blood. 2020 Apr 30;135(18):1603-1606.
7. Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH Jr, Winton EF, Parker DR, Lee H, Reister-Schultz A, Savage S, Stevens E, Brockett C, Subbiah N, Press RD, Raess PW, Cascio M, Dunlap J, Chen Y, Degnin C, Maxson JE, Tognon CE, Macey T, Druker BJ, Tyner JW. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. Journal of Clinical Oncology. 2020 Apr 1;38(10):1006-1018.
8. Braun TP, Okhovat M, Coblentz C, Carratt SA, Foley A, Schonrock Z, Nevonen K, Davis B, Garcia B, LaTocha D, Weeder BR, Grzadkowski MR, Estabrook JC, Manning HG, Watanabe-Smith K, Smith JL, Leonti AR, Ries RE, Jeng S, McWeeney S, Di Genua C, Drissen R, Nerlov C, Meshinchi S, Carbone L, Druker BJ and Maxson JE. Myeloid Lineage Enhancers Drive Oncogene Synergy in CEBPA/CSF3R Mutant Acute Myeloid Leukemia. Nature Communications. 2019 Nov 29;20(1):5455.
9. Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister-Schultz A, Long N, White L, Carlos A, Henson RA, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Than H, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW. Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis. Blood. 2019 Sep 12;134(11):867-879.
10. Spiciarich DR, Oh ST, Foley A, Hughes SB, Mauro MJ, Abdel-Wahab O, Press RD, Viner R, Thompson SL, Chen Q, Azadi P, Bertozzi C, Maxson JE. A novel germline variant in CSF3R reduces N-glycosylation and exerts potent oncogenic effects in leukemia. Cancer Research. 2018 Dec 15;78(24):6762-6770.
11. Jenkins C, Luty SB, Maxson JE, Eide CA, Abel ML, Togiai C, Nemecek ER, Bottomly D, McWeeney SK, Wilmot B, Loriaux M, Chang BH, Tyner JW. Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia. Science Signalling. 2018 Jul;11 (539).
12. Zhang H, Coblentz C, Watanabe-Smith K, Means S, Means J, Maxson JE, Tyner JW. Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation. J Biol Chem. 2018 May; 293(19):7387-7396. 
13. Khanna V, Eide CE, Tognon C, Maxson JE, Wilmot B, Bottomly D, McWeeney S, Edwards D, Druker BJ, Tyner JW. Recurrent cyclin D2 mutations in myeloid neoplasms. Leukemia. 2017 Sep;31(9):2005-2008.
14. Maxson JE, Tyner JW. Genomics of Chronic Neutrophilic Leukemia. Blood. 2017 Feb; 129(6):715-722.
15. Maxson JE, Ries R, Wang Y-C, Gerbing RB, Kolb EA, Thompson SL, Guidry Auvil JM, Marra MA, Ma Y, Zong S, Mungall AJ, Moore R, Long W, Gesuwan P, Davidsen TM, Hermida LC, Farrar JE, Radich JP, Smith MA, Gerhard DS, Gamis AS, Alonzo TA, and Meshinchi S. CSF3R Mutations have a High Degree of Overlap with CEBPA Mutations in Pediatric AML. Blood. 2016 Jun 16;127(24):3094-8.
16. Maxson JE, Abel ML, Wang J, Xianming D, Reckel S, Luty SB, Sun H, Gorenstein J, Hughes S, Bottomly D, Wilmot B, McWeeney SK, Radich J, Hantschel O, Middleton RE, Gray NS, Druker BJ, and Tyner JW. Identification and characterization of Tyrosine Kinase Non-receptor 2 mutations in leukemia through integration of kinase inhibitor screening and genomic analysis. Cancer Res. 2016 Jan 1;76(1):127-38.
17. Maxson JE, Luty SB, MacManiman JD, Paik J, Gotlib JR, Greenberg P, Bahamadi S, Savage SL, Abel ML, Eide, CA, Loriaux MM, Stevens EA and Tyner JW. The Colony Stimulating Factor 3 Receptor T640N mutation is oncogenic and mimics T618I. Clinical Cancer Research. 2016 Feb 1;22(3)757-64.
18. Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, Jordan CT, Lee C-K, Swisshelm K, Tobin J, Wei Q, Schowinsky J, Rinella S, Lee HG, and Pollyea DA. Clonality of Neutrophilia Associated with Plasma Cell Neoplasms: Report of a SETBP1 Mutation and Analysis of a Single Institution Series. Leukemia and Lymphoma. 2016;57(4):927-34.
19. Maxson JE, Davare MA, Luty SB, Eide CA, Chang BH, Loriaux MM, Tognon CE, Druker BJ and Tyner JW. Therapeutically-targetable ALK point mutations in leukemia. Cancer Research. Jun 1, 2015; 75(11):2146-50.
20. Braun TP, Maxson JE, Agarwal A, Dunlap J, Spurgeon SE and Traer E. Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome. Leukemia Research Reports. 2015; 4(1):8-11.
21. Dao KT, Solti MB, Maxson JE, Winton EF, Press RD, Druker BJ, Tyner JW. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. Leukemia Research Reports. 2014 Aug 1;3(2)67-9.
22. Maxson JE, Luty SB, Abel ML, Druker BJ, Tyner JW. Ligand-independence of the colony stimulating factor 3 receptor (CSF3R) T618I mutation results from loss of O-linked glycosylation and increased receptor dimerization. Journal of Biological Chemistry. 2014 Feb 28;289(9):5820-7.
23. Fleischman AG*, Maxson JE*, Luty SB, Agarwal A, Royer LR, Abel ML, Macmaniman JD, Loriaux MM, Druker BJ, Tyner JW. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 2013 Sept 30. 
24. Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, Ketterling RP,     Maxson JE, Tyner JW, and Tefferi A. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013 Sept 27; (9):1870-3.
25. Gotlib J, Maxson JE, George TI, and Tyner JW. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood. 2013 Sep 5; 122(10):1707-11.
26. Braun TP, Grossberg AJ, Krasnow SM, Levasseur PR, Szumowski M, Zhu XX, Maxson JE, Knoll JG, Barnes AP and Marks DL. Cancer- and Endotoxin-Induced Cachexia Require Intact Glucocorticoid Signaling in Skeletal Muscle. FASEB. 2013 Sept 27: 3572-82.
27. Maxson JE, Jason Gotlib JR, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney S, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW. Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML. The New England Journal of Medicine. 2013 May 9;368(19):1781-90.